Review



il 6 neutralising antibodies  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Sino Biological il 6 neutralising antibodies
    Exosomal HMGB1 activates JAK/STAT3 signalling to promote NSCLC progression. (A) Protein–protein interaction (PPI) network analysis of HMGB1 using the STRING database. (B) Western blot analysis of NF‐κB in A549 and PC9 cells treated with PBS, recombinant HMGB1 (100 ng), exosomes from vector cells or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). (C) ELISA quantification <t>of</t> <t>IL‐6</t> in the supernatant of A549 and PC9 cells under the same treatment conditions as in (B). (D) Immunofluorescence staining of p‐STAT3 of A549 and PC9 cells under the same treatments, including an additional group co‐treated with exosomes from HMGB1 OE cells and NF‐κB inhibitor (50 μM). (E) Cell proliferation of A549 and PC9 cells treated with HMGB1 OE‐derived exosomes alone or in combination with NF‐κB inhibitor (50 μM) or STAT3 inhibitor (20 μM). (F) Cell migration under the same treatment conditions as in (E). (G) Colony formation assays of A549 and PC9 cells under the same treatment conditions as in (E).
    Il 6 Neutralising Antibodies, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 28 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/Anti-IL6/pmc12877720-49-0-6
    Average 94 stars, based on 28 article reviews
    il 6 neutralising antibodies - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade"

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade

    Journal: Journal of Cellular and Molecular Medicine

    doi: 10.1111/jcmm.71050

    Exosomal HMGB1 activates JAK/STAT3 signalling to promote NSCLC progression. (A) Protein–protein interaction (PPI) network analysis of HMGB1 using the STRING database. (B) Western blot analysis of NF‐κB in A549 and PC9 cells treated with PBS, recombinant HMGB1 (100 ng), exosomes from vector cells or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). (C) ELISA quantification of IL‐6 in the supernatant of A549 and PC9 cells under the same treatment conditions as in (B). (D) Immunofluorescence staining of p‐STAT3 of A549 and PC9 cells under the same treatments, including an additional group co‐treated with exosomes from HMGB1 OE cells and NF‐κB inhibitor (50 μM). (E) Cell proliferation of A549 and PC9 cells treated with HMGB1 OE‐derived exosomes alone or in combination with NF‐κB inhibitor (50 μM) or STAT3 inhibitor (20 μM). (F) Cell migration under the same treatment conditions as in (E). (G) Colony formation assays of A549 and PC9 cells under the same treatment conditions as in (E).
    Figure Legend Snippet: Exosomal HMGB1 activates JAK/STAT3 signalling to promote NSCLC progression. (A) Protein–protein interaction (PPI) network analysis of HMGB1 using the STRING database. (B) Western blot analysis of NF‐κB in A549 and PC9 cells treated with PBS, recombinant HMGB1 (100 ng), exosomes from vector cells or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). (C) ELISA quantification of IL‐6 in the supernatant of A549 and PC9 cells under the same treatment conditions as in (B). (D) Immunofluorescence staining of p‐STAT3 of A549 and PC9 cells under the same treatments, including an additional group co‐treated with exosomes from HMGB1 OE cells and NF‐κB inhibitor (50 μM). (E) Cell proliferation of A549 and PC9 cells treated with HMGB1 OE‐derived exosomes alone or in combination with NF‐κB inhibitor (50 μM) or STAT3 inhibitor (20 μM). (F) Cell migration under the same treatment conditions as in (E). (G) Colony formation assays of A549 and PC9 cells under the same treatment conditions as in (E).

    Techniques Used: Western Blot, Recombinant, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Derivative Assay, Migration

    Targeting HMGB1 signalling improves therapeutic outcomes in NSCLC. (A) Correlation analysis between immune infiltration scores and HMGB1 expression in 491 LUAD and 500 LUSC patients from the TCGA database. (B) Correlation between HMGB1 expression and the distribution of various immune cell subsets in LUAD and LUSC patients. (C, D) THP‐1–derived M0 macrophages were treated with PBS, HMGB1 (10 or 100 ng) or exosomes derived from vector or HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). M1 macrophage markers (CD86, CD80, iNOS) and M2 markers (CD206, IL‐10, Arg1) were quantified by PCR. (E) Lewis tumour‐bearing mice were treated with PBS, HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse, twice per week), anti‐PD‐1 antibody (RMP1‐14, 200 μg per mouse, twice per week) or combination therapy ( n = 5 per group). Tumour volumes and apoptosis levels in tumour tissues (day 25) were assessed. (F) PC9 cells were treated with PBS or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10), followed by Osimertinib (50 nM, 48 h), and apoptosis was measured. (G) A549 and PC9 cells were similarly treated with PBS or HMGB1 OE‐derived exosomes, followed by Cisplatin (5 μM, 48 h), and apoptosis was analysed. (H) A549 and PC9 cells were similarly treated with paclitaxel (10 μM, 48 h) under the same conditions, and cell apoptosis was determined. (I) A549‐bearing mice were treated with HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse), followed by PBS, paclitaxel (PTX, 10 mg/kg, twice per week), STAT3 inhibitor (5 mg/kg, twice per week) or combination therapy. (J) Schematic diagram illustrating the proposed mechanism: HMGB1 upregulates TLR4, thereby activating the NF‐κB–IL‐6 axis and stimulating JAK2/STAT3 signalling to promote tumour progression. Concurrently, HMGB1 facilitates M2 macrophage polarisation.
    Figure Legend Snippet: Targeting HMGB1 signalling improves therapeutic outcomes in NSCLC. (A) Correlation analysis between immune infiltration scores and HMGB1 expression in 491 LUAD and 500 LUSC patients from the TCGA database. (B) Correlation between HMGB1 expression and the distribution of various immune cell subsets in LUAD and LUSC patients. (C, D) THP‐1–derived M0 macrophages were treated with PBS, HMGB1 (10 or 100 ng) or exosomes derived from vector or HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). M1 macrophage markers (CD86, CD80, iNOS) and M2 markers (CD206, IL‐10, Arg1) were quantified by PCR. (E) Lewis tumour‐bearing mice were treated with PBS, HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse, twice per week), anti‐PD‐1 antibody (RMP1‐14, 200 μg per mouse, twice per week) or combination therapy ( n = 5 per group). Tumour volumes and apoptosis levels in tumour tissues (day 25) were assessed. (F) PC9 cells were treated with PBS or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10), followed by Osimertinib (50 nM, 48 h), and apoptosis was measured. (G) A549 and PC9 cells were similarly treated with PBS or HMGB1 OE‐derived exosomes, followed by Cisplatin (5 μM, 48 h), and apoptosis was analysed. (H) A549 and PC9 cells were similarly treated with paclitaxel (10 μM, 48 h) under the same conditions, and cell apoptosis was determined. (I) A549‐bearing mice were treated with HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse), followed by PBS, paclitaxel (PTX, 10 mg/kg, twice per week), STAT3 inhibitor (5 mg/kg, twice per week) or combination therapy. (J) Schematic diagram illustrating the proposed mechanism: HMGB1 upregulates TLR4, thereby activating the NF‐κB–IL‐6 axis and stimulating JAK2/STAT3 signalling to promote tumour progression. Concurrently, HMGB1 facilitates M2 macrophage polarisation.

    Techniques Used: Expressing, Derivative Assay, Plasmid Preparation

    Related Articles

    Western Blot:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.

    Recombinant:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.

    Plasmid Preparation:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.

    Enzyme-linked Immunosorbent Assay:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.

    Immunofluorescence:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.

    Staining:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.

    Derivative Assay:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.

    Migration:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.

    Expressing:

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
    Article Snippet: All cell lines were regularly tested for mycoplasma contamination.All cell lines were regularly tested for mycoplasma contamination.. IL‐6 neutralising antibodies were obtained from Sino Biological (China).. NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.NF‐κB‐IN‐3 (NF‐κB inhibitor, HY‐144744, MedChemExpress, USA) and STAT3‐IN‐3 (STAT3 inhibitor, HY‐128588, MedChemExpress, USA) were obtained from MedChemExpress.



    Similar Products

    anti-il-6 neutralising antibody  (Thermo Fisher)
    90
    Thermo Fisher anti-il-6 neutralising antibody
    Anti Il 6 Neutralising Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/pm37668685-78-38-42
    Average 90 stars, based on 1 article reviews
    anti-il-6 neutralising antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    il 6 neutralising antibodies  (Sino Biological)
    94
    Sino Biological il 6 neutralising antibodies
    Exosomal HMGB1 activates JAK/STAT3 signalling to promote NSCLC progression. (A) Protein–protein interaction (PPI) network analysis of HMGB1 using the STRING database. (B) Western blot analysis of NF‐κB in A549 and PC9 cells treated with PBS, recombinant HMGB1 (100 ng), exosomes from vector cells or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). (C) ELISA quantification <t>of</t> <t>IL‐6</t> in the supernatant of A549 and PC9 cells under the same treatment conditions as in (B). (D) Immunofluorescence staining of p‐STAT3 of A549 and PC9 cells under the same treatments, including an additional group co‐treated with exosomes from HMGB1 OE cells and NF‐κB inhibitor (50 μM). (E) Cell proliferation of A549 and PC9 cells treated with HMGB1 OE‐derived exosomes alone or in combination with NF‐κB inhibitor (50 μM) or STAT3 inhibitor (20 μM). (F) Cell migration under the same treatment conditions as in (E). (G) Colony formation assays of A549 and PC9 cells under the same treatment conditions as in (E).
    Il 6 Neutralising Antibodies, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/Anti-IL6/pmc12877720-49-0-6
    Average 94 stars, based on 1 article reviews
    il 6 neutralising antibodies - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    mdt discussion and consensus for treatment with remdesivir il 6 blockade neutralising antibodies  (Gilead Sciences)
    99
    Gilead Sciences mdt discussion and consensus for treatment with remdesivir il 6 blockade neutralising antibodies
    Suggested initial admission checklist for pregnant women admitted to hospital.
    Mdt Discussion And Consensus For Treatment With Remdesivir Il 6 Blockade Neutralising Antibodies, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/VEKLURY/pmc08938185-8-0-8
    Average 99 stars, based on 1 article reviews
    mdt discussion and consensus for treatment with remdesivir il 6 blockade neutralising antibodies - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    rat anti-mouse il-6 neutralising antibody  (Thermo Fisher)
    90
    Thermo Fisher rat anti-mouse il-6 neutralising antibody
    Suggested initial admission checklist for pregnant women admitted to hospital.
    Rat Anti Mouse Il 6 Neutralising Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/rat+anti+mouse+il+6+neutralising+antibody/pmc08365448-105-15-20
    Average 90 stars, based on 1 article reviews
    rat anti-mouse il-6 neutralising antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    anti-il-6 neutralising antibody clone mp520f3  (Thermo Fisher)
    90
    Thermo Fisher anti-il-6 neutralising antibody clone mp520f3
    Suggested initial admission checklist for pregnant women admitted to hospital.
    Anti Il 6 Neutralising Antibody Clone Mp520f3, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/mouse+il6+efluor+450/pmc08365448-192-3-8
    Average 90 stars, based on 1 article reviews
    anti-il-6 neutralising antibody clone mp520f3 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    il6 neutralising antibody  (R&D Systems)
    94
    R&D Systems il6 neutralising antibody
    Wnt-dependent breast CSC colony formation is promoted by IL1β. a Gene expression levels of Wnt ligands did not increase from week 3 to week 8 bone marrow taken from three patients (patient numbers: 140, 147, 148). Data is presented as log2 fold change in gene expression from week 3 to week 8. b Treating bone marrow in culture with 100 µM porcupine inhibitor (PORCNi) LGK974 for 72 h prior to taking CM did not prevent CM stimulating mammosphere formation in MCF-7 cells (PORCNi on BM). Treating MCF-7 cells with 100 µM of LGK974 for 72 h prior to the addition of CM prevented stimulation in mammosphere formation (PORCNi on MCF7). c IL15 and IL1β showed the largest increase from week 3 to week 8 CM when analysed by cytokine array ( n = 1). d Inhibition of <t>IL6,</t> IL8 or IL15 with 5 µg/ml <t>neutralising</t> antibody did not prevent induction of mammosphere formation by CM in MCF-7 cells, whereas inhibition of IL1β with 5 µg/ml neutralising antibody prevented CM from increasing mammosphere formation. e IL1β levels were significantly increased in week 8–12 stimulatory CM compared to week 3 non-stimulatory CM ( n = 4). f IL1β is expressed by both normal mouse and human bone. Staining is representative of three sections from three independent samples. Femur taken from 8 week old NSG mice. Negative controls (no primary antibody) are shown. Scale bar 100 µM. g The addition of 10 ng/ml recombinant IL1β to control media replicated the effect of CM in stimulating mammosphere formation in MCF-7 and MDA-MB-231_BH. h Treating a bone marrow sample in culture with 5 µg/ml of IL1β neutralising antibody for 72 h prior to collection of CM prevented stimulation of mammosphere formation in MCF-7 cells (IL1βNA on BM). Treating MCF-7 cells with 5 µg/ml of IL1β neutralising antibody for 72 h prior to the addition of CM did not prevent stimulation in mammosphere formation by CM (IL1βNA on MCF7). i IL1R gene expression is increased in the anoikis resistant (AR) cancer stem cell population in MCF-7 cells. j 10 µg/ml Anakinra reversed the induction in mammosphere formation by CM in early breast cancer samples ( n = 3). All graphs represent mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Il6 Neutralising Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/Human+IL-6+Antibody/pmc06825219-263-65-69
    Average 94 stars, based on 1 article reviews
    il6 neutralising antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    il-6 neutralising antibody  (Tocris)
    90
    Tocris il-6 neutralising antibody
    IL‐6 receptor‐alpha (IL‐6Rα) was present in NeuN‐positive cells in the central amygdala and IL ‐6 stimulated the firing rate of neurones residing in the capsular part of the central amygdala. IL ‐6Rα immunoreactivity (green) and NeuN immunoreactivity (red) partially co‐localised in the central amygdala (CeA). Cell nuclei were stained with 4′,6‐diamidino‐2‐phenylindole (blue). Yellow arrowheads show examples of cells where IL ‐6Rα and NeuN immunoreactivity co‐localised, whereas green and red arrowheads show examples of cells with only IL ‐6Rα and NeuN immunoreactivity, respectively (A, B). Approximately 50% of IL ‐6Rα‐immunoreactive cells also showed NeuN immunoreactivity. Conversely, approximately 50% of NeuN immunoreactive cells also showed IL ‐6Rα immunoreactivity (C, D). These results indicate that a substantial proportion of the neurones in the CeA could be responsive to IL ‐6. Loose‐patch recording showed that IL ‐6 (1 nmol L ‐1 ) could rapidly increase the firing rate of the targeted neurones. The zoomed periods and frequency distribution graph under the recording also show this profound elevation (E). A cocktail of IL ‐6 and its <t>neutralising</t> antibody ( IL ‐6 ab) evoked no significant change in the firing rate (F). Arrows show the onset of administration of IL ‐6 or the IL ‐6 + IL ‐6ab cocktail. Scale bars: overview = 80 μm, zoom = 10 μm. BLA , basolateral amygdala
    Il 6 Neutralising Antibody, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/il+6+neutralising+antibody/pmc06618171-91-13-21
    Average 90 stars, based on 1 article reviews
    il-6 neutralising antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    neutralising antibody against either il-6 (5μg/ml; clone 6708)  (R&D Systems)
    90
    R&D Systems neutralising antibody against either il-6 (5μg/ml; clone 6708)
    (A) BMMSC or (B) WJMSC co-cultures were cultured in close proximity, on opposite sides of a porous filters for 24h and then treated with neutralising antibodies <t>against</t> <t>IL-6</t> or a function blocking antibody against IL-6R for the duration of the co-culture and <t>cytokine</t> treatment. Neutrophil adhesion was expressed as a proportion of that observed on the paired EC mono-culture. ANOVA showed a significant effect of co-culture treatment on neutrophil adhesion in (A) (p<0.05) and (B) (p<0.01). Data are mean ± SEM, n = 3–4 independent experiments using a different EC and neutrophil donor in each experiment. (A) 3 different BMMSC and (B) 4 different WJMSC donors were used. * = p<0.05 and ** = p<0.01 compared to untreated MSC co-cultures by Dunnett post-test.
    Neutralising Antibody Against Either Il 6 (5μg/Ml; Clone 6708), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/neutralising+antibody+against+either+il+6++5%CE%BCg+ml++clone+6708+/pmc04865100-92-8-27
    Average 90 stars, based on 1 article reviews
    neutralising antibody against either il-6 (5μg/ml; clone 6708) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    human neutralising anti il 6  (R&D Systems)
    93
    R&D Systems human neutralising anti il 6
    (A) BMMSC or (B) WJMSC co-cultures were cultured in close proximity, on opposite sides of a porous filters for 24h and then treated with neutralising antibodies <t>against</t> <t>IL-6</t> or a function blocking antibody against IL-6R for the duration of the co-culture and <t>cytokine</t> treatment. Neutrophil adhesion was expressed as a proportion of that observed on the paired EC mono-culture. ANOVA showed a significant effect of co-culture treatment on neutrophil adhesion in (A) (p<0.05) and (B) (p<0.01). Data are mean ± SEM, n = 3–4 independent experiments using a different EC and neutrophil donor in each experiment. (A) 3 different BMMSC and (B) 4 different WJMSC donors were used. * = p<0.05 and ** = p<0.01 compared to untreated MSC co-cultures by Dunnett post-test.
    Human Neutralising Anti Il 6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/Human+IL-6+Antibody/pm25150006-78-12-16
    Average 93 stars, based on 1 article reviews
    human neutralising anti il 6 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti il 6 neutralising antibodies  (R&D Systems)
    91
    R&D Systems anti il 6 neutralising antibodies
    Effect of <t>neutralising</t> anti-IL-6 antibodies on IGF-1 stimulated PHA-induced apoptosis in CBMC culture . Neutralising anti-IL-6 antibodies (1 μg/mL) were added to CBMC cultured in serum free medium with PHA (1 μg/mL) + IGF-1 (100 ng/mL). Anti-IL-6 antibodies abrogated the anti-apoptotic effects of IGF-1. Results shown are mean ± SEM of 7 independent cases (* p < 0.05).
    Anti Il 6 Neutralising Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+6+neutralising+antibodies/IL-6+Antibody+(Medarex+patent+anti-IL-6)/pmc02631546-50-32-35
    Average 91 stars, based on 1 article reviews
    anti il 6 neutralising antibodies - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Exosomal HMGB1 activates JAK/STAT3 signalling to promote NSCLC progression. (A) Protein–protein interaction (PPI) network analysis of HMGB1 using the STRING database. (B) Western blot analysis of NF‐κB in A549 and PC9 cells treated with PBS, recombinant HMGB1 (100 ng), exosomes from vector cells or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). (C) ELISA quantification of IL‐6 in the supernatant of A549 and PC9 cells under the same treatment conditions as in (B). (D) Immunofluorescence staining of p‐STAT3 of A549 and PC9 cells under the same treatments, including an additional group co‐treated with exosomes from HMGB1 OE cells and NF‐κB inhibitor (50 μM). (E) Cell proliferation of A549 and PC9 cells treated with HMGB1 OE‐derived exosomes alone or in combination with NF‐κB inhibitor (50 μM) or STAT3 inhibitor (20 μM). (F) Cell migration under the same treatment conditions as in (E). (G) Colony formation assays of A549 and PC9 cells under the same treatment conditions as in (E).

    Journal: Journal of Cellular and Molecular Medicine

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade

    doi: 10.1111/jcmm.71050

    Figure Lengend Snippet: Exosomal HMGB1 activates JAK/STAT3 signalling to promote NSCLC progression. (A) Protein–protein interaction (PPI) network analysis of HMGB1 using the STRING database. (B) Western blot analysis of NF‐κB in A549 and PC9 cells treated with PBS, recombinant HMGB1 (100 ng), exosomes from vector cells or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). (C) ELISA quantification of IL‐6 in the supernatant of A549 and PC9 cells under the same treatment conditions as in (B). (D) Immunofluorescence staining of p‐STAT3 of A549 and PC9 cells under the same treatments, including an additional group co‐treated with exosomes from HMGB1 OE cells and NF‐κB inhibitor (50 μM). (E) Cell proliferation of A549 and PC9 cells treated with HMGB1 OE‐derived exosomes alone or in combination with NF‐κB inhibitor (50 μM) or STAT3 inhibitor (20 μM). (F) Cell migration under the same treatment conditions as in (E). (G) Colony formation assays of A549 and PC9 cells under the same treatment conditions as in (E).

    Article Snippet: IL‐6 neutralising antibodies were obtained from Sino Biological (China).

    Techniques: Western Blot, Recombinant, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Derivative Assay, Migration

    Targeting HMGB1 signalling improves therapeutic outcomes in NSCLC. (A) Correlation analysis between immune infiltration scores and HMGB1 expression in 491 LUAD and 500 LUSC patients from the TCGA database. (B) Correlation between HMGB1 expression and the distribution of various immune cell subsets in LUAD and LUSC patients. (C, D) THP‐1–derived M0 macrophages were treated with PBS, HMGB1 (10 or 100 ng) or exosomes derived from vector or HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). M1 macrophage markers (CD86, CD80, iNOS) and M2 markers (CD206, IL‐10, Arg1) were quantified by PCR. (E) Lewis tumour‐bearing mice were treated with PBS, HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse, twice per week), anti‐PD‐1 antibody (RMP1‐14, 200 μg per mouse, twice per week) or combination therapy ( n = 5 per group). Tumour volumes and apoptosis levels in tumour tissues (day 25) were assessed. (F) PC9 cells were treated with PBS or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10), followed by Osimertinib (50 nM, 48 h), and apoptosis was measured. (G) A549 and PC9 cells were similarly treated with PBS or HMGB1 OE‐derived exosomes, followed by Cisplatin (5 μM, 48 h), and apoptosis was analysed. (H) A549 and PC9 cells were similarly treated with paclitaxel (10 μM, 48 h) under the same conditions, and cell apoptosis was determined. (I) A549‐bearing mice were treated with HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse), followed by PBS, paclitaxel (PTX, 10 mg/kg, twice per week), STAT3 inhibitor (5 mg/kg, twice per week) or combination therapy. (J) Schematic diagram illustrating the proposed mechanism: HMGB1 upregulates TLR4, thereby activating the NF‐κB–IL‐6 axis and stimulating JAK2/STAT3 signalling to promote tumour progression. Concurrently, HMGB1 facilitates M2 macrophage polarisation.

    Journal: Journal of Cellular and Molecular Medicine

    Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade

    doi: 10.1111/jcmm.71050

    Figure Lengend Snippet: Targeting HMGB1 signalling improves therapeutic outcomes in NSCLC. (A) Correlation analysis between immune infiltration scores and HMGB1 expression in 491 LUAD and 500 LUSC patients from the TCGA database. (B) Correlation between HMGB1 expression and the distribution of various immune cell subsets in LUAD and LUSC patients. (C, D) THP‐1–derived M0 macrophages were treated with PBS, HMGB1 (10 or 100 ng) or exosomes derived from vector or HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). M1 macrophage markers (CD86, CD80, iNOS) and M2 markers (CD206, IL‐10, Arg1) were quantified by PCR. (E) Lewis tumour‐bearing mice were treated with PBS, HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse, twice per week), anti‐PD‐1 antibody (RMP1‐14, 200 μg per mouse, twice per week) or combination therapy ( n = 5 per group). Tumour volumes and apoptosis levels in tumour tissues (day 25) were assessed. (F) PC9 cells were treated with PBS or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10), followed by Osimertinib (50 nM, 48 h), and apoptosis was measured. (G) A549 and PC9 cells were similarly treated with PBS or HMGB1 OE‐derived exosomes, followed by Cisplatin (5 μM, 48 h), and apoptosis was analysed. (H) A549 and PC9 cells were similarly treated with paclitaxel (10 μM, 48 h) under the same conditions, and cell apoptosis was determined. (I) A549‐bearing mice were treated with HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse), followed by PBS, paclitaxel (PTX, 10 mg/kg, twice per week), STAT3 inhibitor (5 mg/kg, twice per week) or combination therapy. (J) Schematic diagram illustrating the proposed mechanism: HMGB1 upregulates TLR4, thereby activating the NF‐κB–IL‐6 axis and stimulating JAK2/STAT3 signalling to promote tumour progression. Concurrently, HMGB1 facilitates M2 macrophage polarisation.

    Article Snippet: IL‐6 neutralising antibodies were obtained from Sino Biological (China).

    Techniques: Expressing, Derivative Assay, Plasmid Preparation

    Suggested initial admission checklist for pregnant women admitted to hospital.

    Journal: Obstetric Medicine

    Article Title: Considerations for women with COVID-19 admitted to hospital

    doi: 10.1177/1753495X221083504

    Figure Lengend Snippet: Suggested initial admission checklist for pregnant women admitted to hospital.

    Article Snippet: MDT discussion and consensus for treatment with: - Remdesivir - Il-6 blockade - Neutralising antibodies , .

    Techniques:

    Wnt-dependent breast CSC colony formation is promoted by IL1β. a Gene expression levels of Wnt ligands did not increase from week 3 to week 8 bone marrow taken from three patients (patient numbers: 140, 147, 148). Data is presented as log2 fold change in gene expression from week 3 to week 8. b Treating bone marrow in culture with 100 µM porcupine inhibitor (PORCNi) LGK974 for 72 h prior to taking CM did not prevent CM stimulating mammosphere formation in MCF-7 cells (PORCNi on BM). Treating MCF-7 cells with 100 µM of LGK974 for 72 h prior to the addition of CM prevented stimulation in mammosphere formation (PORCNi on MCF7). c IL15 and IL1β showed the largest increase from week 3 to week 8 CM when analysed by cytokine array ( n = 1). d Inhibition of IL6, IL8 or IL15 with 5 µg/ml neutralising antibody did not prevent induction of mammosphere formation by CM in MCF-7 cells, whereas inhibition of IL1β with 5 µg/ml neutralising antibody prevented CM from increasing mammosphere formation. e IL1β levels were significantly increased in week 8–12 stimulatory CM compared to week 3 non-stimulatory CM ( n = 4). f IL1β is expressed by both normal mouse and human bone. Staining is representative of three sections from three independent samples. Femur taken from 8 week old NSG mice. Negative controls (no primary antibody) are shown. Scale bar 100 µM. g The addition of 10 ng/ml recombinant IL1β to control media replicated the effect of CM in stimulating mammosphere formation in MCF-7 and MDA-MB-231_BH. h Treating a bone marrow sample in culture with 5 µg/ml of IL1β neutralising antibody for 72 h prior to collection of CM prevented stimulation of mammosphere formation in MCF-7 cells (IL1βNA on BM). Treating MCF-7 cells with 5 µg/ml of IL1β neutralising antibody for 72 h prior to the addition of CM did not prevent stimulation in mammosphere formation by CM (IL1βNA on MCF7). i IL1R gene expression is increased in the anoikis resistant (AR) cancer stem cell population in MCF-7 cells. j 10 µg/ml Anakinra reversed the induction in mammosphere formation by CM in early breast cancer samples ( n = 3). All graphs represent mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: Nature Communications

    Article Title: Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling

    doi: 10.1038/s41467-019-12807-0

    Figure Lengend Snippet: Wnt-dependent breast CSC colony formation is promoted by IL1β. a Gene expression levels of Wnt ligands did not increase from week 3 to week 8 bone marrow taken from three patients (patient numbers: 140, 147, 148). Data is presented as log2 fold change in gene expression from week 3 to week 8. b Treating bone marrow in culture with 100 µM porcupine inhibitor (PORCNi) LGK974 for 72 h prior to taking CM did not prevent CM stimulating mammosphere formation in MCF-7 cells (PORCNi on BM). Treating MCF-7 cells with 100 µM of LGK974 for 72 h prior to the addition of CM prevented stimulation in mammosphere formation (PORCNi on MCF7). c IL15 and IL1β showed the largest increase from week 3 to week 8 CM when analysed by cytokine array ( n = 1). d Inhibition of IL6, IL8 or IL15 with 5 µg/ml neutralising antibody did not prevent induction of mammosphere formation by CM in MCF-7 cells, whereas inhibition of IL1β with 5 µg/ml neutralising antibody prevented CM from increasing mammosphere formation. e IL1β levels were significantly increased in week 8–12 stimulatory CM compared to week 3 non-stimulatory CM ( n = 4). f IL1β is expressed by both normal mouse and human bone. Staining is representative of three sections from three independent samples. Femur taken from 8 week old NSG mice. Negative controls (no primary antibody) are shown. Scale bar 100 µM. g The addition of 10 ng/ml recombinant IL1β to control media replicated the effect of CM in stimulating mammosphere formation in MCF-7 and MDA-MB-231_BH. h Treating a bone marrow sample in culture with 5 µg/ml of IL1β neutralising antibody for 72 h prior to collection of CM prevented stimulation of mammosphere formation in MCF-7 cells (IL1βNA on BM). Treating MCF-7 cells with 5 µg/ml of IL1β neutralising antibody for 72 h prior to the addition of CM did not prevent stimulation in mammosphere formation by CM (IL1βNA on MCF7). i IL1R gene expression is increased in the anoikis resistant (AR) cancer stem cell population in MCF-7 cells. j 10 µg/ml Anakinra reversed the induction in mammosphere formation by CM in early breast cancer samples ( n = 3). All graphs represent mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: Cell lines and patient derived samples were treated with the following prior to downstream assays: 50 ng/ml DKK1 (GF170, Milipore), 50 μg/ml Vantictumab (Oncomed), 100 nm Wnt3A (5036-WN, R&D systems), 100 μM LGK974 (S7143, Selleckchem), 10 ng/ml rIL15 (247-ILB, R&D systems), 10 ng/ml rIL1β (201-LB, R&D systems), 5 μg/ml IL1β neutralising antibody (MAB201, R&D systems), 5 μg/ml IL15 neutralising antibody (MAB-274, R&D systems), 5 μg/ml IL6 neutralising antibody (MAB2061, R&D systems), 5 μg/ml IL8 neutralising antibody (MAB208, R&D systems), 10 μg/ml Anakinra (Amgen, Cambridge, UK), 5 mM Sulfasalazine (Sigma), 10uM KG-501 (Sigma).

    Techniques: Gene Expression, Inhibition, Staining, Recombinant, Control

    IL‐6 receptor‐alpha (IL‐6Rα) was present in NeuN‐positive cells in the central amygdala and IL ‐6 stimulated the firing rate of neurones residing in the capsular part of the central amygdala. IL ‐6Rα immunoreactivity (green) and NeuN immunoreactivity (red) partially co‐localised in the central amygdala (CeA). Cell nuclei were stained with 4′,6‐diamidino‐2‐phenylindole (blue). Yellow arrowheads show examples of cells where IL ‐6Rα and NeuN immunoreactivity co‐localised, whereas green and red arrowheads show examples of cells with only IL ‐6Rα and NeuN immunoreactivity, respectively (A, B). Approximately 50% of IL ‐6Rα‐immunoreactive cells also showed NeuN immunoreactivity. Conversely, approximately 50% of NeuN immunoreactive cells also showed IL ‐6Rα immunoreactivity (C, D). These results indicate that a substantial proportion of the neurones in the CeA could be responsive to IL ‐6. Loose‐patch recording showed that IL ‐6 (1 nmol L ‐1 ) could rapidly increase the firing rate of the targeted neurones. The zoomed periods and frequency distribution graph under the recording also show this profound elevation (E). A cocktail of IL ‐6 and its neutralising antibody ( IL ‐6 ab) evoked no significant change in the firing rate (F). Arrows show the onset of administration of IL ‐6 or the IL ‐6 + IL ‐6ab cocktail. Scale bars: overview = 80 μm, zoom = 10 μm. BLA , basolateral amygdala

    Journal: Journal of Neuroendocrinology

    Article Title: Interleukin‐6 in the central amygdala is bioactive and co‐localised with glucagon‐like peptide‐1 receptor

    doi: 10.1111/jne.12722

    Figure Lengend Snippet: IL‐6 receptor‐alpha (IL‐6Rα) was present in NeuN‐positive cells in the central amygdala and IL ‐6 stimulated the firing rate of neurones residing in the capsular part of the central amygdala. IL ‐6Rα immunoreactivity (green) and NeuN immunoreactivity (red) partially co‐localised in the central amygdala (CeA). Cell nuclei were stained with 4′,6‐diamidino‐2‐phenylindole (blue). Yellow arrowheads show examples of cells where IL ‐6Rα and NeuN immunoreactivity co‐localised, whereas green and red arrowheads show examples of cells with only IL ‐6Rα and NeuN immunoreactivity, respectively (A, B). Approximately 50% of IL ‐6Rα‐immunoreactive cells also showed NeuN immunoreactivity. Conversely, approximately 50% of NeuN immunoreactive cells also showed IL ‐6Rα immunoreactivity (C, D). These results indicate that a substantial proportion of the neurones in the CeA could be responsive to IL ‐6. Loose‐patch recording showed that IL ‐6 (1 nmol L ‐1 ) could rapidly increase the firing rate of the targeted neurones. The zoomed periods and frequency distribution graph under the recording also show this profound elevation (E). A cocktail of IL ‐6 and its neutralising antibody ( IL ‐6 ab) evoked no significant change in the firing rate (F). Arrows show the onset of administration of IL ‐6 or the IL ‐6 + IL ‐6ab cocktail. Scale bars: overview = 80 μm, zoom = 10 μm. BLA , basolateral amygdala

    Article Snippet: In a second experimental group of neurones, a cocktail of IL‐6 and a IL‐6 neutralising antibody (1 mol L ‐1 ; Tocris Bioscience, St Louis, MO, USA) was applied after the initial recording of basal firing.

    Techniques: Staining

    (A) BMMSC or (B) WJMSC co-cultures were cultured in close proximity, on opposite sides of a porous filters for 24h and then treated with neutralising antibodies against IL-6 or a function blocking antibody against IL-6R for the duration of the co-culture and cytokine treatment. Neutrophil adhesion was expressed as a proportion of that observed on the paired EC mono-culture. ANOVA showed a significant effect of co-culture treatment on neutrophil adhesion in (A) (p<0.05) and (B) (p<0.01). Data are mean ± SEM, n = 3–4 independent experiments using a different EC and neutrophil donor in each experiment. (A) 3 different BMMSC and (B) 4 different WJMSC donors were used. * = p<0.05 and ** = p<0.01 compared to untreated MSC co-cultures by Dunnett post-test.

    Journal: PLoS ONE

    Article Title: Comparative Ability of Mesenchymal Stromal Cells from Different Tissues to Limit Neutrophil Recruitment to Inflamed Endothelium

    doi: 10.1371/journal.pone.0155161

    Figure Lengend Snippet: (A) BMMSC or (B) WJMSC co-cultures were cultured in close proximity, on opposite sides of a porous filters for 24h and then treated with neutralising antibodies against IL-6 or a function blocking antibody against IL-6R for the duration of the co-culture and cytokine treatment. Neutrophil adhesion was expressed as a proportion of that observed on the paired EC mono-culture. ANOVA showed a significant effect of co-culture treatment on neutrophil adhesion in (A) (p<0.05) and (B) (p<0.01). Data are mean ± SEM, n = 3–4 independent experiments using a different EC and neutrophil donor in each experiment. (A) 3 different BMMSC and (B) 4 different WJMSC donors were used. * = p<0.05 and ** = p<0.01 compared to untreated MSC co-cultures by Dunnett post-test.

    Article Snippet: In some experiments, a neutralising antibody against either IL-6 (5μg/ml; clone 6708) or a function blocking antibody against membrane IL-6 receptor (IL-6R; 5μg/ml; clone 17506; all from R&D Systems) was added when co-cultures were established in close proximity on opposite sides of porous insert and were present throughout the co-culture and cytokine-stimulation.

    Techniques: Cell Culture, Blocking Assay, Co-Culture Assay

    MSC-EC co-cultures were formed (A) in direct contact using channel slides; (B, D-E) in close proximity on opposite sides of a porous filter; or (C) in close proximity or with MSC seeded below and separate from EC on the filter above. EC and MSC mono-cultures (at p3 for WJMSC and p5 for BMMSC) were set up as controls. IL-6 release into supernatants was assessed after 24h. In (D) and (E), ANOVA showed a significant effect of culture conditions, p<0.01. Data are mean ± SEM from (A) n = 4–8 (B) n = 3–19 where EC mono-cultures (n = 19); BMMSC mono-cultures (n = 13); EC:BMMSC (n = 16); WJMSC mono-cultures (n = 3); EC:WJMSC (n = 10); TBMSC mono-cultures (n = 4); EC:TBMSC (n = 7), (C-E) n = 3 independent experiments using a different EC and neutrophil donor in each experiment. (A-E) 5 different BMMSC, 3 different WJMSC and 3 different TBMSC donors were used. ** = p<0.01 compared to the sum of the EC and respective MSC mono-cultures supernatant unless otherwise indicated by paired t-test in A-C, or by Dunnett post-test in D-E.

    Journal: PLoS ONE

    Article Title: Comparative Ability of Mesenchymal Stromal Cells from Different Tissues to Limit Neutrophil Recruitment to Inflamed Endothelium

    doi: 10.1371/journal.pone.0155161

    Figure Lengend Snippet: MSC-EC co-cultures were formed (A) in direct contact using channel slides; (B, D-E) in close proximity on opposite sides of a porous filter; or (C) in close proximity or with MSC seeded below and separate from EC on the filter above. EC and MSC mono-cultures (at p3 for WJMSC and p5 for BMMSC) were set up as controls. IL-6 release into supernatants was assessed after 24h. In (D) and (E), ANOVA showed a significant effect of culture conditions, p<0.01. Data are mean ± SEM from (A) n = 4–8 (B) n = 3–19 where EC mono-cultures (n = 19); BMMSC mono-cultures (n = 13); EC:BMMSC (n = 16); WJMSC mono-cultures (n = 3); EC:WJMSC (n = 10); TBMSC mono-cultures (n = 4); EC:TBMSC (n = 7), (C-E) n = 3 independent experiments using a different EC and neutrophil donor in each experiment. (A-E) 5 different BMMSC, 3 different WJMSC and 3 different TBMSC donors were used. ** = p<0.01 compared to the sum of the EC and respective MSC mono-cultures supernatant unless otherwise indicated by paired t-test in A-C, or by Dunnett post-test in D-E.

    Article Snippet: In some experiments, a neutralising antibody against either IL-6 (5μg/ml; clone 6708) or a function blocking antibody against membrane IL-6 receptor (IL-6R; 5μg/ml; clone 17506; all from R&D Systems) was added when co-cultures were established in close proximity on opposite sides of porous insert and were present throughout the co-culture and cytokine-stimulation.

    Techniques:

    Effect of neutralising anti-IL-6 antibodies on IGF-1 stimulated PHA-induced apoptosis in CBMC culture . Neutralising anti-IL-6 antibodies (1 μg/mL) were added to CBMC cultured in serum free medium with PHA (1 μg/mL) + IGF-1 (100 ng/mL). Anti-IL-6 antibodies abrogated the anti-apoptotic effects of IGF-1. Results shown are mean ± SEM of 7 independent cases (* p < 0.05).

    Journal: BMC Immunology

    Article Title: Insulin-like growth factor I promotes cord blood T cell maturation through monocytes and inhibits their apoptosis in part through interleukin-6

    doi: 10.1186/1471-2172-9-74

    Figure Lengend Snippet: Effect of neutralising anti-IL-6 antibodies on IGF-1 stimulated PHA-induced apoptosis in CBMC culture . Neutralising anti-IL-6 antibodies (1 μg/mL) were added to CBMC cultured in serum free medium with PHA (1 μg/mL) + IGF-1 (100 ng/mL). Anti-IL-6 antibodies abrogated the anti-apoptotic effects of IGF-1. Results shown are mean ± SEM of 7 independent cases (* p < 0.05).

    Article Snippet: To neutralise the effect of IL-6, CBMC were cultured for 4 days at 1 × 10 6 cells/mL in DMEM-F12 containing IGF-1 (100 ng/mL) + PHA (1 μg/mL) and 1–20 μg/mL of anti-IL-6 neutralising antibodies (R&D System, Minneapolis, USA).

    Techniques: Cell Culture